Contributions
Abstract: PB1420
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Core-binding factor acute myeloid leukemia (CBF-AML) belong to the cytogenetic favourable risk group. Although the prognosis of CBF-AML is better than other cytogenetic groups, 30 to 40% of patients will experience relapse and require stem cell transplantation.
Aims
In this study we aimed to assess treatment outcome of CBF- AML treated in in our hospital.
Methods
We retrospectively evaluated outcomes of CBF-AML treated at the hematology department of Aziza Othmana hospital between 2010 and 2019. All patients had cytogenetic at diagnosis. Only few patients had fusion genes study.
For all patients, induction consisted of idarubicine 12mg/m2 per day on days 1 to 3 and cytarabine 200mg/m2 per day over 7 days. Patients in complete remission had 3 consolidations consisting of high dose cytarabine.
Results
Five hundred and twenty-one AML adult patients were treated during the period of study. 32 patients had CBF-AML (6.1%). Median age was 34.5 years (range 20 to 56 y). Median WBC at diagnosis was 16.9 G/L (range 0.3 to 86.4 G/L). 78.1% of patients had inv 16 (p13;q22) and 21.9% had t(8;21) (q22;q22). 11 patients had additional cytogenetic abnormalities.
One patient died during induction. Complete remission was achieved in 90% of CBF-AML. Relapse occurred in 9 patients (31%) at a median of 12.9 months (range 5.4 to 48.5 months). A second remission was obtained in 77.7% of patients. Allogeneic stem cell transplantation was performed in only 3 patients. Median overall survival (OS) and relapse free survival (RFS) at 5 years were 60%.
Conclusion
In our study, Complete remission was achieved in 90 % of the CBF-AML patients. It is consistent with published results. Long term survival in our series compared favourably with results reported by cooperative groups.
In our study very few CBF-AML patients in relapse had stem cell transplantation. In fact, in our country allogeneic stem cell transplantation is performed in only one center receiving patients from all the country and is limited to young patients having an HLA-matched sibling donor.
Our results could be improved using autologous system cell transplantation which can be considered as a part of post remission therapy in CBF-AML offering superior RFS an OS in favourable risk AML in first remission compared to chemotherapy.
Keyword(s): AML, Chemotherapy, Cytogenetic abnormalities
Abstract: PB1420
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Core-binding factor acute myeloid leukemia (CBF-AML) belong to the cytogenetic favourable risk group. Although the prognosis of CBF-AML is better than other cytogenetic groups, 30 to 40% of patients will experience relapse and require stem cell transplantation.
Aims
In this study we aimed to assess treatment outcome of CBF- AML treated in in our hospital.
Methods
We retrospectively evaluated outcomes of CBF-AML treated at the hematology department of Aziza Othmana hospital between 2010 and 2019. All patients had cytogenetic at diagnosis. Only few patients had fusion genes study.
For all patients, induction consisted of idarubicine 12mg/m2 per day on days 1 to 3 and cytarabine 200mg/m2 per day over 7 days. Patients in complete remission had 3 consolidations consisting of high dose cytarabine.
Results
Five hundred and twenty-one AML adult patients were treated during the period of study. 32 patients had CBF-AML (6.1%). Median age was 34.5 years (range 20 to 56 y). Median WBC at diagnosis was 16.9 G/L (range 0.3 to 86.4 G/L). 78.1% of patients had inv 16 (p13;q22) and 21.9% had t(8;21) (q22;q22). 11 patients had additional cytogenetic abnormalities.
One patient died during induction. Complete remission was achieved in 90% of CBF-AML. Relapse occurred in 9 patients (31%) at a median of 12.9 months (range 5.4 to 48.5 months). A second remission was obtained in 77.7% of patients. Allogeneic stem cell transplantation was performed in only 3 patients. Median overall survival (OS) and relapse free survival (RFS) at 5 years were 60%.
Conclusion
In our study, Complete remission was achieved in 90 % of the CBF-AML patients. It is consistent with published results. Long term survival in our series compared favourably with results reported by cooperative groups.
In our study very few CBF-AML patients in relapse had stem cell transplantation. In fact, in our country allogeneic stem cell transplantation is performed in only one center receiving patients from all the country and is limited to young patients having an HLA-matched sibling donor.
Our results could be improved using autologous system cell transplantation which can be considered as a part of post remission therapy in CBF-AML offering superior RFS an OS in favourable risk AML in first remission compared to chemotherapy.
Keyword(s): AML, Chemotherapy, Cytogenetic abnormalities